West Cancer Center joins ChoICE study for breast cancer cryoablation

The clinical effort, led by Dr. Richard Gilmore at the Margaret West Comprehensive Breast Center, focuses on low-risk, early-stage breast cancer patients. ProSense uses liquid-nitrogen-based technology to destroy tumors by freezing them, offering a surgical alternative for those receiving adjuvant endocrine therapy. This development follows the company’s ICE3 trial, which reported a 3.1% local recurrence rate and high patient satisfaction regarding cosmetic outcomes.

The ChoICE study aims to gather further real-world data across 30 participating sites. These locations will operate with a dual purpose: conducting the formal study while simultaneously offering ProSense as a commercial option for eligible patients who fall outside the trial parameters. This expansion signals a broader push to increase access to cryoablation as a standard of care for aging populations dealing with biologically low-risk tumors under 1.5 cm.